Skip to main content
GutCited
Figure 4. Clustering of multivariate data using principal component analysis analysis of responses for different variables of quality of life from Test-G (G) and Placebo-H (H) arms at end of treatment (visit 04). Variables considered are— abdominal pain,
Figure 5. Figure 4. Clustering of multivariate data using principal component analysis analysis of responses for different variables of quality of life from Test-G (G) and Placebo-H (H) arms at end of treatment (visit 04). Variables considered are— abdominal pain, diarrhea, constipation, bloating and flatulence, vomiting and nausea, perception of mental well-being, and influence on daily life.

الوصف

Principal component analysis of quality of life responses clusters patients by treatment arm. Bacillus coagulans-treated patients show greater separation from baseline values, indicating improved quality of life dimensions.

More Figures from This Paper

Total IBS symptom scores decrease significantly in the Bacillus coagulans LBSC group compared to placebo over the treatment period. Both bloating and abdominal pain subscores show improvement.

Figure 2

Total IBS symptom scores decrease significantly in the Bacillus coagulans LBSC group compared to placebo over the treatment period. Both bloating and abdominal pain subscores show improvement.

chart
Individual IBS symptom domains including bloating, abdominal pain, urgency, and incomplete evacuation are tracked across study visits. Bacillus coagulans supplementation shows benefits across multiple symptom dimensions.

Figure 3

Individual IBS symptom domains including bloating, abdominal pain, urgency, and incomplete evacuation are tracked across study visits. Bacillus coagulans supplementation shows benefits across multiple symptom dimensions.

chart
Stool consistency changes from baseline to end of treatment are assessed using the Bristol Stool Form Scale. The Bacillus coagulans group shows normalization toward type 3-4 stools compared to placebo.

Figure 4

Stool consistency changes from baseline to end of treatment are assessed using the Bristol Stool Form Scale. The Bacillus coagulans group shows normalization toward type 3-4 stools compared to placebo.

chart

Figure 5

Chart
962 × 368px · 81,8 ك.ب

Source Paper

Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT …

Medicine (2021)

PMID: 33545934

DOI: 10.1097/MD.0000000000023641

Cite This Figure

![Figure 5: Principal component analysis of quality of life responses clusters patients by treatment arm. Bacillus coagulans-treated patients show greater separation from baseline values, indicating improved quality of life dimensions.](https://pdfs.citedhealth.com/figures/33545934/159.png)

> Source: Anil Kumar Gupta et al. "Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A pr." *Medicine*, 2021. PMID: [33545934](https://pubmed.ncbi.nlm.nih.gov/33545934/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/33545934/159.png" alt="Principal component analysis of quality of life responses clusters patients by treatment arm. Bacillus coagulans-treated patients show greater separation from baseline values, indicating improved quality of life dimensions." />
  <figcaption>Figure 5. Principal component analysis of quality of life responses clusters patients by treatment arm. Bacillus coagulans-treated patients show greater separation from baseline values, indicating improved quality of life dimensions.<br>  Source: Anil Kumar Gupta et al. "Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A pr." <em>Medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33545934/">33545934</a></figcaption>
</figure>

أدلة ذات صلة

B
Bacillus coagulans لـ Irritable Bowel Syndrome (IBS)

التقييم B · 3 دراسات